# Self-passivated bilayer black phosphorus QDs based multifunctional nanoparticles for tumor immune reprogramming

**Authors:** Tingting Liu, Wenyan She, Ruili Du, Yali Bao, Zhibin Guo, Qichao Gao, Hanping Li, Pengfei Suo, Yi Liu, Yujiao Liu

PMC · DOI: 10.1016/j.mtbio.2026.102862 · Materials Today Bio · 2026-02-02

## TL;DR

Researchers developed a safe and effective nanoplatform using self-passivated black phosphorus quantum dots to enhance tumor treatment and imaging.

## Contribution

The study introduces a novel nanoplatform (BD3PP) combining photothermal, photodynamic, and targeted therapies for tumor immune reprogramming.

## Key findings

- Self-passivated bilayer BPQDs showed superior photothermal and photodynamic therapy efficiency compared to non-passivated forms.
- BD3PP induced immunogenic cell death and promoted M1 macrophage polarization to remodel the tumor microenvironment.
- DFT calculations confirmed BPQD degradation into biocompatible phosphoric acid, ensuring biosafety.

## Abstract

It is important yet challenging to enhance immunotherapy responses using biosafe agents due to the immunosuppressive tumor microenvironment. To address this challenge, BD3PP was constructed by encapsulating black phosphorus quantum dots (BPQDs), a synthesized thioredoxin reductase inhibitor 3c, and Dir (the fluorescent dye) into PLGA nanoparticles, followed by conjugation with a PDL1 antagonist for synergistic multimodal therapy and imaging. The mechanism and efficiency of BD3PP were investigated through density functional theory (DFT) calculations, molecular docking, and in vitro and in vivo experiments. The PDL1 antagonist served as a targeting moiety that binds PDL1 on the tumor cell surface, enabling the controlled intracellular release of the three therapeutic agents. Self-passivated bilayer BPQDs converted optical energy into heat for photothermal therapy and generated singlet oxygen (1O2) from O2 for type II photodynamic therapy, showing far superior to non-passivated bilayer BPQDs or bulk BP. Meanwhile, 3c selectively inhibited thioredoxin reductase, leading to the production of ·O2‐ and H2O2. These effects synergistically induced immunogenic cell death (ICD), promoted macrophage polarization toward the M1 phenotype, and remodeled the tumor microenvironment to facilitate tumor clearance. The near-infrared fluorescent dye Dir enabled real-time imaging both in vitro and in vivo. DFT calculation revealed that BPQDs were ultimately degraded into biocompatible phosphoric acid. Along with the other biocompatible components in BD3PP, biosafety was guaranteed. This research introduces an efficient and biosafe nanoplatform based on self-passivated bilayer BPQDs, which exhibits prolonged blood circulation and enhanced multimodal real-time photothermal and near-infrared imaging. Importantly, this nanoplatform enables integrated photothermal, photodynamic, and targeted therapies, demonstrating promising potential for anti-tumor preclinical and clinical applications.

Image 1

•Ultrasmall, homogeneous, self-passivated bilayer BPQDs were successfully prepared.•The PDT mechanism and the biodegradation of BPQDs were firstly investigated by DFT.•BD3PP induced ICD to remodel the tumor microenvironment to clear tumors.•BD3PP prolonged blood circulation, multimode imaging and therapy efficiency.

Ultrasmall, homogeneous, self-passivated bilayer BPQDs were successfully prepared.

The PDT mechanism and the biodegradation of BPQDs were firstly investigated by DFT.

BD3PP induced ICD to remodel the tumor microenvironment to clear tumors.

BD3PP prolonged blood circulation, multimode imaging and therapy efficiency.

## Linked entities

- **Chemicals:** 3c (PubChem CID 139166958), Dir (PubChem CID 25195411), phosphoric acid (PubChem CID 1004), singlet oxygen (PubChem CID 159832), O2 (PubChem CID 977), ·O2− (PubChem CID 977), H2O2 (PubChem CID 784)
- **Diseases:** tumor (MONDO:0005070)

## Full-text entities

- **Genes:** Calr (calreticulin) [NCBI Gene 12317] {aka CRT, Calregulin}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, Bax (BCL2-associated X protein) [NCBI Gene 12028], Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, PDCD1 (programmed cell death 1) [NCBI Gene 5133] {aka ADMIO4, AIMTBS, CD279, PD-1, PD1, SLEB2}, Blnk (B cell linker) [NCBI Gene 17060] {aka BASH, Bca, Ly-57, Ly57, Lyw-57, SLP-65}, H2 (histocompatibility-2, MHC) [NCBI Gene 111364] {aka H-2, MHC-II}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Cd274 (CD274 antigen) [NCBI Gene 60533] {aka A530045L16Rik, B7h1, Pdcd1l1, Pdcd1lg1, Pdl1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Prdx2 (peroxiredoxin 2) [NCBI Gene 21672] {aka Band-8, NkefB, PRP, PrxII, TDX1, TPx}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Dppa1 (developmental pluripotency associated 1) [NCBI Gene 347708], Bcl2 (B cell leukemia/lymphoma 2) [NCBI Gene 12043] {aka Bcl-2, C430015F12Rik, D630044D05Rik, D830018M01Rik}, Foxp3 (forkhead box P3) [NCBI Gene 20371] {aka JM2, scurfin, sf}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 14433] {aka Gapd}, PRDX5 (peroxiredoxin 5) [NCBI Gene 25824] {aka ACR1, AOEB166, B166, HEL-S-55, PLP, PMP20}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}
- **Diseases:** inflammation (MESH:D007249), Tumor (MESH:D009369), lung cancer (MESH:D008175), swelling (MESH:D004487), Hemolysis (MESH:D006461), metastasis (MESH:D009362), leukemia (MESH:D007938), ICD (MESH:D003643), infection (MESH:D007239), BPQDs (MESH:D010760), TNBC (MESH:D064726), breast cancer (MESH:D001943), necrosis (MESH:D009336)
- **Chemicals:** 2,2,6,6-Tetramethylpiperidine (MESH:C551336), singlet oxygen (MESH:D026082), 1-Methyl-2-pyrrolidinone (MESH:C038678), calcein AM (MESH:C085925), O (MESH:D010100), BP (MESH:D010758), PI (MESH:D010716), TCEP (MESH:C080938), phosphorus oxides (MESH:C012500), BDP (MESH:D001507), streptomycin (MESH:D013307), PVA (MESH:C063253), Coomassie Brilliant Blue (MESH:C004692), NaN3 (MESH:D019810), H2O (MESH:D014867), LA (MESH:D007811), 2,7 -dichlorofluorescein diacetate (MESH:C029569), peptide (MESH:D010455), Tn (MESH:C009497), SDS (MESH:D012967), Sn (MESH:D014001), Hydroxyl radicals (MESH:D017665), 2,2,6,6-tetramethylpiperidine-1-oxyl (MESH:C003959), H&amp;E (MESH:D006371), S (MESH:D013455), H2O2 (MESH:D006861), propidium iodide (MESH:D011419), superoxide (MESH:D013481), 3c (-), penicillin (MESH:D010406), Hoechst 33342 (MESH:C017807), phosphoric acid (MESH:C030242), thiol (MESH:D013438), polyvinyl alcohol (MESH:D011142), oil (MESH:D009821), TiO2 (MESH:C009495), CO2 (MESH:D002245), BP (MESH:C038809), ATP (MESH:D000255), MAL (MESH:C043592), 1,3-Diphenylisobenzofuran (MESH:C011238), Cys (MESH:D003545), 5,5-Dimethyl-1-pyrroline N-oxide (MESH:C017245), H (MESH:D006859), As (MESH:D001151), PBS (MESH:D007854), GA (MESH:D005708), PLGA (MESH:D000077182), Sec (MESH:D017279), ROS (MESH:D017382), DAPI (MESH:C007293), DMSO (MESH:D004121)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** S25 — Mus musculus (Mouse), Hybridoma (CVCL_G585), RAW — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_F681), COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), 4T1 — Mus musculus (Mouse), Malignant neoplasms of the mouse mammary gland, Cancer cell line (CVCL_0125), S21 — Mus musculus (Mouse), Transformed cell line (CVCL_K245), BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914194/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914194/full.md

## References

50 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914194/full.md

---
Source: https://tomesphere.com/paper/PMC12914194